Safety and Efficacy of Transurethral Bipolar Enucleation of Prostate (TUBE) in BPH

Objectives: To evaluate the safety and efficacy of transurethral bipolar enucleation of the prostate due to benign prostatic hyperplasia. Methods: This is a prospective study and 37 patients undergoing Transurethral bipolar enucleation of the prostate (TUBE) for BPH will be taken for the study. Preoperative factors evaluated included International Prostate Symptom Score (IPSS), postvoid residual volume (PVR), estimated blood loss, operative time, pathologic weight, and complications. Postoperative evaluation was performed at 1month, 6 months and 12months. Results: Preoperative, 1 month, 6 months, and 12 months mean postvoid residual volumes were 235 mL, 33.6 mL, 20 mL and 20 mL; mean IPSS were 31.6, 2.97, 2.97 and 2.97; mean Q max was 5.8ml/sec, 20.23ml/sec,25.5ml/sec, and 25.5ml/sec; preoperative and post operative mean quality of life scores were 5.4 and 2.2; mean operative time was 87.5 minutes. Hemoglobin drop was 0.6g/dl, and pathologic weight was 45.45 g. 10 patients underwent partial enucleation. Early stress incontinence occurred in 9 patients (24.3%). Urinary tract infection occurred in 1 patient, and Superficial mucosal bladder injury in 1 patient. Conclusions: International Prostate Symptom Score, quality of life, Qmax, and postvoid residual volume (PVR) showed statistically significant improvements from baseline. TUBE is a safe, effective, and reproducible procedure for BPH. A study of 37 patients who underwent TUBE were followed up for 12 months and found that the procedure resulted in minimal morbidity, with immediate improvements in symptoms and voiding. In the current study, TUBE showed that this procedure has a low morbidity rate and is an alternative to TURP in the treatment of patients with symptomatic BPH. Our results provide evidence supporting the efficacy of TUBE. Improvements in subjective variables (IPSS and QOL) showed that the patients were satisfied with the results of this procedure. At 1 year, mean Qmax improved 13.9 to 25.5 ml/s; mean PVR urine decreased from 40.22ml to 0 ml volume, mean IPSS at preop & 1month after follow up decreased from 31.6 to 2.97 and mean QOL scores after 12months improved from 5 to 2, when compared with preoperative data. The highly significant improvements from baseline in postoperative PVR and QOL index showed that the obstruction had been successfully relieved [Fig